Startups
Avata Biosciences
Clinical-stage neuroscience pharmaceutical company, formerly Sapient Therapeutics, developing prescription cannabinoid medicines for epilepsy and other neurological and psychiatric disorders. Its formulation technology turns synthetic cannabidiol into water-soluble preparations and solid oral doses for adult and pediatric patients. Its published pipeline includes focal epilepsy and schizophrenia programs. Avata operates across the UK, US and Australia and licenses its programs to Oceanus Bio for development in Japan and other Asian markets excluding China and India. Its UK holding company was incorporated in April 2022; the Avata rebrand was announced in May 2024.
Founded 2022
Team
Investments
No investment rounds on record yet.